These authors have contributed to the work in the same way.
Oncogenic HPVs are necessarily involved in cervical cancer but their role in oral carcinogenesis is debated. To detect HPV in oral cancer, 38 cases of formalin fixed-paraffin embedded OSCC were studied by both DNA genotyping (MY09/11 Ll consensus primers in combination with GP5-GP6 primer pair followed by sequencing) and immunohistochemistry (monoclonal Abs against capsid protein and HPV-E7 protein, KIH8 DAKO and clone 8C9 INVITROGEN, respectively). HPV-16 tonsil cancer was used as positive control. The overall prevalence of HPV infection in OSCCs was 10.5%. Amplification of DNA samples showed single HPV DNA infection in 3 cases (HPVI6; HPV53; HPV70) and double infection in one case of cheek cancer (HPV311HPV44). The overall HR-HPV prevalence was 7.5%. E-7 antigen was immunohistochemically detected in all HPV-positive cases. HPV+ OSCC cases showed an overall better outcome than HPV negative oral cancers, as evaluated by Kaplan-Meier curves. HPVs exert their oncogenic role after DNA integration, gene expression ofE5, E6 and E710ci and p53/pRb host proteins suppression. This study showed that HPV-E7 protein inactivating pRb is expressed in oral cancer cells infected by oncogenic HPV other than classical HR-HPV-16/18. Interestingly HPV-70, considered a low risk virus with no definite collocation in oncogenic type category, gives rise to the expression of HPV-E7 protein and inactivate pRb in oral cancer. HPV-70, as proved in current literature, is able to inactivates also p53 protein, promoting cell immortalization. HPV-53, classified as a possible high risk virus, expresses E7 protein in OSCC, contributing to oral carcinogenesis. We have identified among OSCCs, a subgroup characterized by HPV infection (10.5lYo). Finally, we have proved the oncogenic potential of some HPV virus types, not well known in literature.
Oral Squamous Cell Carcinoma (OSCC) is the sixth most common cancer and accounts for approximately 5% of all malignant tumors worldwide and a subgroup of OSCC have been demonstrated to contain anogenital HPV infection. The high risk HPV type 16 tends to be the most predominant type detected in oral cancer (1).
HPVs are a group of host specific DNA virus with a remarkable epithelial cell specificity. More than 120 different HPV genotypes have been identified and almost 45 subtypes, isolated from the low genital tract, have been grouped into high-and low-risk HPV types, considering their potential risk to induce an invasive cervical cancer (2) . Up to now, data about HPV prevalence in oral infection, risk factors, genetic pathway, molecular pathogenesis, and its potential oncogenic role in oral carcinogenesis are very scanty (3) .
The involvement of a virus in carcinogenesis is demonstrated after its integration in host DNA with consequent expression of oncogenic proteins. (4, 5) .
Therefore, the new interesting approach to the study of the oral cancer should be based on the understanding of its molecular viral background and on the detection of over-expressed viral oncoproteins. These proteins may be target of therapeutic vaccines against cancer. Indeed the L1 region of HPV DNA could not be expressed in cancer cells while HPV E-6 and E7 are necessarily involved in cancer cell blocking host tumor suppressor genes (6, 7) .
Aims of this work are to detect HPV in oral cancer, to perform genotyping and demonstrate the oncogenic protein E7 in oral cancer.
The investigation of oncogenic gene expression in HPV-related osee and the study of its potential value as predictor of neoplastic progression and clinical outcome could allow characterization of a possible evolutive morphologycal profile of oral cancer and its precancerous lesions.
The employment of biomarkers improves the current diagnostic tools but also can contribute indirectly to therapeutics as predictor of choice for the correct clinical management.
MATERIALS AND METHODS

Study population
The study group was composed of 38 patients with OSCC, coming from north and middle of Italy, undergone oral maxillofacial surgery at the 'Ospedale Regionale Torrette -Ancona; mean age was 63.06 years (range 44-84). Informed consent was obtained from all participants or from their relatives. The histopathological diagnosis of OSCC was consecutively made at the Section of Anatomic Pathology -Universita Politecnica delle Marche -Ancona, and, then, confirmed at the Section of Anatomic Pathology of the University of Foggia -Foggia. Microscopic evaluation was performed by two oral pathologists, determining the entity of inflammatory infiltrate (WADA), the degree of differentiation according to WHO grading system (8) , and establishing tumor extent according to the TNM system (9) .
Tissues
Archival formalin-fixed, paraffin-embedded human tonsil cancer and 38 OSCCs of oral sites were obtained from Surgery Registry of Tumors at the Ospedale Torrette -Ancona from 1997 to 2005.
All samples were routinely fixed in 10% neutral buffered formalin and embedded in paraffin blocks. Selection of paraffin blocks was based on examination of one haematoxylin and eosin-stained slide to estimate the malignant area of tissue. Paraffin blocks with corresponding normal epithelium distant from tumor were also selected. Surgical dissection of tumor was performed on selected paraffin blocks. Five 10 j.lM sections were cut from each formalin-fixed, paraffin-embedded tumor sample and transferred into microcentrifuge tubes.
Dna extraction
The paraffin samples were dissolved using xylene followed by two washes with 100%ethanol and one wash with phosphatebuffered saline. The samples were then incubated in lysis solution (proteinase K -Qiagen,20mglml, 50 micro-L; 1 M Tris HCl solution, 10 micro-L; 0,5M EDTA, 2 micro-L; 10% SDS 0.7 M) and incubating at 65°C for 4 h. DNA was recovered using the Wizard DNA clean-up kit (Promega, Madison, WI) according to the manufacturer's protocols. To test the integrity of isolated DNA the wide beta-globin gene was amplified by PCR and visualized by gel electrophoresis for both control and pathological samples. The beta-globin gene primers used were: forward, 5' -GAA GAG CCAAGG ACA GGT AC-3', and reverse, 5'-GGAAAA TAG ACC AATAGG CAG 3'.
peR analysis
HPV DNA presence was researched by nested PCR (MYI GP primers), and HPV genotype was determined by direct sequencing of PCR fragments. Three types of control were included in each reaction series: blank control, HPV-negative Wi cells as negative control and HPV-18 DNA-positive HeLa cells, in dilutions from 20,000-50,000 down to 2-5 HPV DNA copies, as positive control. HPV DNA was amplified by PCR assay (MY09-MYll primer pair in combination with GP5-GP6 primer pair) as previously described (10) and amplifications were performed in a DNA thermal cycler (Mastercycler gradient; Eppendorf, Hamburg, Germany); amplification products were analyzed in 8% polyacrylamide gel.
Sequencing analysis
HPV genotyping was based on direct sequencing of MY or MYIGP PCR fragments. Amplification products were purified by Microcon YM-100 (Amicon-Millipore, Billerica, MA); the sequence of both DNA strands was determined by the BigDye Ready Reaction Kit in the automatic sequencer ABI Prism 310 Analyzer (both from Perkin-Elmer Applied Biosystems, Foster City, CA). Alignments were obtained from the GenBank on-line BLAST server and HPV sequences downloaded from the HPV database (http://hpv-web.1anl.gov).
Immunohistochemical analysis
Immunohistochemistry was performed on the sections mounted on poly-L-lysine-coated glass slides, by standard LSAB-HRP technique, as previously described (11, 12) using specific monoclonal antibodies against HPV-E7 (anti HPVI6-E7, mouse monoclonal, Zymed Laboratories, clone 8C9; anti HPV-E7, mouse monoclonal, DAKO, clone KIH8). This type of antibody must be used in high concentration because of the low E7 protein levels in infected cells. Only HPV DNA positive cases with strong E7 immunostaining in all cells have been considered E7 positive OSCCs.
Human HPVI6+ tonsil SCC tissue was used as a positive control, and a negative control was performed by omitting incubation with primary antibody replaced by mouse IgG (DakoCytomation) diluted at the same concentration. Negative control slides without primary antibody were included for each staining.
Finally, 38 cases offormalin fixed-paraffin embedded OSCC were studied by both DNA genotyping (MY09/ 11 L1 consensus primers in combination with GP5-GP6 primer pair followed by sequencing) and immunohistochemistry (specific monoclonal Abs against capsid protein and HPV-E7 protein, KIH8 DAKO and clone 8C9 INVITROGEN, respectively).
RESULTS
Clinicopatholog ical characteristics of patients and
HPV status have been shown in Table 1 .
The overall prevalence of HPV infection in OSCCs was 10.5%. Amplification of DNA samples showed single HPV DNA infection in 3 cases (HPV I6; HPV53; HPV70) and double infection in one case ofcheek cancer (HPV31/ HPV44).
The overall HR-HPV prevalence was 7.8%. E-7 antigen was immunohistochemically detected in all HPV-positive cases ( Figure I) . Interestingly, the majority of HPV positive OSCCs were moderately poorly differentiated. About oral sub-site location, we founded two HR-HPV positive cases (HPVI6; HPV53) and one LR-HPV (HPV70) in Waldayer's ring area. Outside Waldayer's area we founded j ust one mixed LR-HPV and HR HPV infection (HPV31-44).
Furthermore, tumor histological characteristics of HPV-positive patients differed from those of HPVnegative patients (Figure 2 ). HPV-positive OSCCs were 
In the same case (f) note the massive presence ofgiant cells and lymphocytic infiltration (LSAB-HRp, nuclear counterstaining with haematoxylin, original magnification x40).
more likely than HPV-negative tumors to be moderately differentiated, to show areas of comedo-like necrosis and to arise prevalently from tongue-base. Since this is a mucosal associated lymphoid tissue (MALT) area HPV positive tumors show intense infiltration of resident lymphocytes, plasma cells and multinucleated giant cells.
Particularly, the HPV 16 positive cancer exhibited also basaloid features, with a lobular and solid pattern of growth, peripheral palisading cell and prominent nuclear basophilia, due to high nuclear to cytoplasmic ratio, not seen in HPV-negative squamous cell carcinomas. The morphologic hallmark of HPV infection, also known as koilocytic atypia, characterized by a sharply outlined perinuclear vacuolation, dense peripheral cytoplasm, one or multiple enlarged nucleus with undulating nuclear membrane and a rope-like chromatin pattern, was typically not plain in the major part of HPV positive tumors. Only the double infected carcinoma (HPV31/44) has shown evident sign of koilocytosis close to comedolike necrosis areas.
All these histological findings provide further evidence that HPV-positive OSCCs are a unique morphological entity distinct from HPV-negative tumors. HPV+ OSCC cases showed an overall better outcome than HPV-negative oral cancers, as evaluated by Kaplan-Meier curves. Following stratification by Stage we demonstrated in each group (II, III, IV; stage I excluded) a worse prognosis for HPV-negative cancer (Figure 3 ). Furthermore, we showed a better prognosis in HPV positive cases characterized by high chronic inflammatory infiltrate (WADA 2-3), also constituted by giant multinucleated cells and by histological areas of comedo-like necrosis, if compared to HPV negative carcinomas with low inflammatory score (WADA 0-1)(P<0.05) (Figure 3 ).
According to site and perineural infiltration, we have noted for each group (tongue cancers and OSCCs from other sites; with and without perineural infiltration) a worse outcome for HPV-negative carcinomas.
DISCUSSION
Several factors are involved in oral carcinogenesis, such as age, gender, ethnicity, lifestyle, genetic background, status of health and exposure to one or more oncogenic factors. In several epidemiologic studies, tobacco smoking and alcohol consumption have been well documented as major risk factors for oral cancer, with attributable fractions of approximately 90%. However, 15-20% of head-and-neck squamous cell carcinomas have no known tobacco or alcohol exposure (13) . Thus, other agents, such as viruses, are being investigated. In particular, with regard to viral involvement, it is still highly controversial whether HR-HPV, widely reported as one of the prominent mechanism behind the development of squamous cell carcinoma, can also be considered an aetiological or a malignant risk factor in oral carcinogenesis (14) .
Links between HPV and oral cavity cancer have been suggested, though the association is less well established. Some research groups (10) have identified HR-HPV antigens and viral DNA in potentially malignant and premalignant oral lesions, and others have defined HR-HPV as playing an important role in OSCC, especially in the absence of common oral habits. Consistent with the existing literature (15) , our data highlighted the evidence that HPV positive oral squamous cell carcinomas are different type of cancer, with a distinct clinical history and with characteristichistologicalfindings.
A very wide range of HPV (0-100%) prevalence in oral cancer (16) has been reported in literature and this widespread variability can only be in part due to the cancer site, geographic location and study sample size. Up to now, the exact proportion of oral cancer attributable to viral infection is unclear. The International Agency on Treatment of Cancer (IARC) Multicenter Study estimated that 18% of oro-pharynx cancers worldwide are HPV associated (17) (18) .
The higher percentage value of viral prevalence, reported and discussed in literature, derives from methodological bias (19) , because of the HPV prevalence has been often estimated on different type of squamous cancer arisen from different sites in the head and neck district: oral cavity, Waldeyer's area and oro-pharynx (20) .
We have identified, in the oral cavity, among OSCCs, a subgroup characterized by HPV infection (10.5%), with overall HR-HPV frequency of 7.8% (2.6% respectively for HPVI6, HPV31 and HPV 53), percentage values not at all unconspicuous. Furthermore, we have proved the oncogenic potential of some HPV virus types, not well known in literature. Particularly, outside Waldeyer's ring area we have frequently detected LR-HPV (HPV44), also in association with a HR-HPV (HPV31). Interestingly, HPV-70, considered a low risk virus with no definite collocation in oncogenic type category, gives rise to the expression of HPV-E7 protein and inactivate pRb in a Waldeyer's ring cancer. HPV-70, as proved in current literature, is able to inactivate also p53 protein, promoting cell immortalization. This study showed that HPV-E7 protein inactivating pRb is expressed in oral cancer cells infected by oncogenic LR-HPV other than classical HR-HPVI6/18.
Our data underline the pathogenetic role of HPVs in oral carcinogenesis different from the classical oncogenic viruses detected in cervical squamous cell carcinomas. We have proved that LR-HPVs and potential high risk viruses with a not well known oncogenic potential may take part in oral carcinogenesis, by inhibiting p53 and by strengthening the oncogenic activity ofHR-HPVs.
In our study, HPV DNA was detected by both PCR analyses, DNA genotyping followed by sequencing and by immunohistochemical valuation of E7 oncoprotein.
In this study, we have observed a subgroup of oral cancer characterized by HPV infection, we have proved the existence ofan oncogenic potential for viruses, known for their low risk oncogenicity or for their no definite collocation in a risk category. We also retain that only standardized technical procedures could assist clinicians to provide innovative and effective treatment and more efficient screening systems for OSCC patients. A specific panel of different HPV types, possibly including LR and HR-viruses, should be defined in order to prepare adequate vaccine reducing the risk of HPV positive oropharyngeal cancers in male and female population.
